This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Trilateral retinoblastoma

Authoring team

Trilateral retinoblastoma is a relatively uncommon condition seen in around 5% to 15% of patients with hereditary retinoblastoma (1,2).

  • it is a primary pineal tumour or an ectopic intracranial tumour which develops in the pineal or suprasellar region in combination with bilateral retinoblastoma (1,3)
  • does not result from metastasis of intraocular retinoblastoma

The condition is usually identified 2 years after the diagnosis of intraocular retinoblastoma (but may occur up to 11 years of age) (2). Patients may present with headache, vomiting, hydrocephalus, and meningismus (3)

Median survival time from diagnosis of the disease has been estimated to be 9 months (2).

  • asymptomatic patients at the time of diagnosis have a better outcome than patients who presents with symptomatic trilateral retinoblastoma (2)
  • routine neuroimaging using magnetic resonance imaging (MRI) in patients with bilateral disease has been recommended (1)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.